Caris Life Sciences (CAI) Gross Profit (2024 - 2026)

Caris Life Sciences' Gross Profit history runs 3 years deep, the most recent figure standing at $171.1 million for Q1 2026.

• In Q1 2026, Gross Profit rose 111.05% year-over-year to $171.1 million; the TTM figure through Mar 2026 stood at $734.6 million (up 145.12% YoY), while the FY2025 annual figure was $644.5 million, up 148.22% from the prior year.
• Gross Profit was $171.1 million for Q1 2026 at Caris Life Sciences, down from $248.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $248.7 million in Q4 2025 to a low of $61.3 million in Q2 2024.
• Historically, Gross Profit has averaged $129.3 million across 3 years, with a median of $115.8 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Gross Profit soared 170.68% in 2025, then jumped 111.05% in 2026.
• A 3-year view of Gross Profit shows it stood at $92.4 million in 2024, then surged by 169.22% to $248.7 million in 2025, then plunged by 31.2% to $171.1 million in 2026.
• The last three Gross Profit figures came in at $171.1 million (Q1 2026), $248.7 million (Q4 2025), and $175.6 million (Q3 2025), per Business Quant data.